Cystic Fibrosis patients attending with infective exacerbations will be enrolled into the study. The trial is a double blinded, randomised trial with patients randomised to 10,14 or 21 days of antibiotic therapy, comprising of tobramycin and either ceftazidime or meropenem.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Enrollment
240
Ceftazidime 2g TDS IV
Tobramycin 7mg/kg/day OD IV
Meropenem 2g TDS IV
Department of Cystic Fibrosis, Royal Brompton Hospital
London, United Kingdom
Treatment failure at completion of antibiotic course
Time frame: 21 days
Time to next exacerbation
Time frame: 6 months
Change in Spirometry
Time frame: up to 21 days
Change in inflammatory markers
Time frame: up to 21 days
Change in sputum bacteriology
Time frame: up to 21 days
Adverse effects of study antibiotics
Time frame: Up to 21 days
Quality of life scores
Time frame: Up to 21 days
Change in nutritional status
Time frame: up to 21 days
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.